More Articles Back to Article
Label expansion approved in Europe for Darzalex, triple-drug combo in MM treatment
Janssen, a division of Johnson & Johnson, has gained European regulators' approval for the label expansion of its combo therapy Darzalex, or daratumumab, combined with bortezomib, thalidomide and dexamethasone, or VTd. The European Commission approved Janssen's marketing authorization for the Darzalex-VTd regimen to treat newly diagnosed multiple myeloma patients qualified to undergo an autologous stem cell transplant. PMLive (UK) (1/21)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!